JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

11.35 8.3

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.48

Max

11.49

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M -20M
Verkäufe	5.9M 40M
Gewinnspanne	-49.569
Angestellte	184
EBITDA	16M -19M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+112.69% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	432M 1.2B
Vorheriger Eröffnungskurs	3.05
Vorheriger Schlusskurs	11.35

Nachrichtenstimmung

By Acuity

50%

151 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 21:40 UTC

Akquisitionen, Fusionen, Übernahmen

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. Feb. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. Feb. 2026, 21:17 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Feb. 2026, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. Feb. 2026, 21:13 UTC

Ergebnisse

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. Feb. 2026, 21:13 UTC

Ergebnisse

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. Feb. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. Feb. 2026, 20:34 UTC

Ergebnisse

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6. Feb. 2026, 20:27 UTC

Ergebnisse

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6. Feb. 2026, 20:24 UTC

Market Talk

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6. Feb. 2026, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6. Feb. 2026, 19:48 UTC

Ergebnisse

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6. Feb. 2026, 19:17 UTC

Market Talk

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6. Feb. 2026, 18:50 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 18:47 UTC

Market Talk

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6. Feb. 2026, 18:34 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6. Feb. 2026, 17:58 UTC

Ergebnisse

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6. Feb. 2026, 17:52 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

6. Feb. 2026, 17:52 UTC

Market Talk

Ergebnisse

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 17:18 UTC

Market Talk

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6. Feb. 2026, 17:09 UTC

Market Talk

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

112.69% Vorteil

12-Monats-Prognose

Durchschnitt 22.29 USD 112.69%

Hoch 29 USD

Tief 16 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

151 / 352 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.